Real time PCR - European Pharmaceutical Review

More documents

Recommendations

Info

PharmaINFOcus A REGULAR ROUND-UP OF INDUSTRY PRODUCTS, INNOVATION, NEWS AND DEVELOPMENTS @ email Carrie Lancaster clancaster@russellpublishing.com Fluidigm systems revolutionise quantative PCR Fluidigm systems alleviate the burdens of intensive pipetting and high reagent costs through the use of integrated fluidic circuits (IFC) — integrated circuits for biology. Thus, Fluidigm systems are igniting exciting advances for traditional and emerging applications in areas such as: ■ Large-scale relative gene expression quantification ■ Single cell gene expression ■ Copy number variation ■ Library quantification for next generation sequencing ■ Gene Expression Quantification at Incredible Throughput. An IFC called the BioMark 96.96 Dynamic Array has the capacity to generate 9,216 data points simultaneously (96 samples x 96 primer-probe pairs), while requiring 100- fold less pipetting. This capability is ideal for validation of candidate genes obtained through microarray screening and for analysis of single cell samples. These capabilities are enabling a revolution in what types of gene expression studies are possible. sensitivity; however, its implementation has historically been too time-consuming for routine laboratory use. Now, a Fluidigm IFC called the 12.765 Digital Array has brought the promise of digital PCR to labs worldwide. The process requires only minutes of hands-on time, and results are available in just a few hours. Since its introduction, the digital array has been proven in multiple applications requiring extreme PCR sensitivity, including the study of variations in copy number, where it allows scientists to distinguish between four and five copies, and sample preparation for next generation sequencing, where it allows scientists to eliminate time consuming and expensive titration steps. Click here for more information about life science with Fluidigm IFCs. About Fluidigm Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturising and integrating liquid handling components on a single microfabricated device. Fluidigm’s IFC systems, consisting of instrumentation, software and single-use IFCs, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use. Digital PCR made fast and easy Digital PCR represents a quantum leap in qPCR resolution and Figure 1: Heat Map. Data obtained with 24 samples and 96 gene expression assays on the 96.96 dynamic array Figure 2: Examples of real-time curves from the 96.96 Dynamic Array Thermo Fisher Scientific expands the utility of high content for toxicity testing Thermo Fisher Scientific has expanded their range of Thermo Scientific Cellomics BioApplication image processing tools for toxicology studies. The new Comet v3.0 BioApplication automates the detection and analysis of the single cell gel electrophoresis assay often used by toxicologists studying the amount of DNA damage caused by compound or radiation exposure. This assay, along with the well established Micronucleus BioApplication, permits scientists to more fully profile compounds for both cytotoxicity and genotoxicity endpoints in a more automated, less subjective manner. Additionally, Thermo scientists have enabled their high content platform to study whole organisms with their soon to be released ZebraTox v3.0 BioApplication which addresses acute toxicity seen in developing zebrafish embryos. As a new tool in organism research, the BioApplication allows for multiple morphological measurements to determine shape changes in zebrafish embryos along with capability to look at fluorescent measurements of targets such as in the Zygogen Z-tag SM fluorescent embryos. www.thermofisher.com 38 www.europeanpharmaceuticalreview.com
PharmaINFOcus A REGULAR ROUND-UP OF INDUSTRY PRODUCTS, INNOVATION, NEWS AND DEVELOPMENTS MDS Pharma Services appoints Dr. Jessica Liu to Lead Clinical Operations in Asia MDS Pharma Services, has appointed Jessica Liu, M.D., to the position of Clinical Operations Director and Head of the Asia-Pacific region for its late-stage clinical trial management division. The appointment supports the MDS business unit’s well-established and growing presence there and strengthens its ability to serve clients in an increasingly important emerging geography. “Dr. Liu brings many years of extensive and relevant global experience in medicine, clinical research and the pharmaceutical industry to this important position,” said MDS Pharma Services President David Spaight. “Her appointment reflects our commitment to provide the highest levels of quality and service to our clients in a region that has emerged as a key arena for global clinical research. Her clinical research experience encompasses a number of therapeutic areas in which MDS Pharma Services specialises, including oncology, diabetes and infectious diseases. ” Prior to joining MDS Pharma Services, Dr. Liu was with Bristol-Myers Squibb (BMS) for ten years, most recently in Brussels where she managed international BMS projects. @ email Carrie Lancaster clancaster@russellpublishing.com IDBS Data Management Solutions deliver proven efficiency and award winning quality After 20 years as a leading provider of data management solutions to research and development industries, IDBS continues to strengthen its profitability and grow its product development. Among significant business advances made in 2008, the company experienced rapid sales growth of its electronic workbook suite (E-WorkBook) and increased adoption of its high throughput screening solution ActivityBase XE. Neil Kipling, founder and CEO of IDBS, commented. "In particular, the market gave a very positive reception to our chemistry tool set, which is competing strongly and replacing She began her career as a resident physician in the Endocrinology Department of the Peking Union Medical College Hospital in Beijing followed by 15 years in clinical research, including leadership roles in clinical operations, project management and medical affairs. Dr. Liu holds a Medical Doctorate degree from China’s prestigious University of Beijing and a Diploma in Pharmaceutical Medicine from the University of Basel in Switzerland. www.mdsps.com Jessica Liu existing legacy solutions that have not kept pace with the changing environment within R&D." He added: "With our clients already reporting 20-30% efficiency savings directly accountable to the implementation of our solutions, we will continue to work hard to maximise their benefit." Unlike its competitors, IDBS continues to invest significantly in product development. "Our competitors believe that they can retain their market share and maintain customer satisfaction by freezing development or asking their customer DxS appoints Jeff Devlin as new Chief Operating Officer DxS Ltd, a personalised medicine company and leaders in the provision of companion diagnostics, has recently announced the appointment of Jeff Devlin as Chief Operating Officer. Prior to DxS, Jeff held positions as Executive VP and Executive Committee member of Shire Pharmaceuticals, where he played a key role in strategy and integration. Before this he was a Partner in Ernst and Young’s life science division. Jeff has a BSc in Physics from the University of Edinburgh and an MSc in Marketing from the University of Strathclyde. Dr. Stephen Little, CEO of DxS, said: “Jeff’s appointment significantly strengthens the DxS management team and with his strong background in operations and strategy, his expertise will be critical as the company continues its planned expansion.” The appointment is one of a number planned for 2009, continuing DxS’ expansion which has seen the company’s workforce more than double in size in the last twelve months with new manufacturing space taken at their Manchester site and a global distribution deal agreed with Roche Molecular Diagnostics for their TheraScreen® diagnostic kits. www.dxsdiagnostics.com base to fund even the most basic product improvements," said Glyn Williams, VP of Product Management. "We believe that we serve our client base better by listening and investing up-front in the solutions we know they require, then offering real products with demonstrable value." A recipient of two Queen’s Awards for Enterprise, IDBS has also recently been awarded the Select Science.Net Scientist’s Choice Award for its E-WorkBook Suite and a prestigious Frost & Sullivan award for the quality and innovation of its professional services. www.idbs.com GO TO CONTENTS PAGE 39
Page 1 and 2: TECHNOLOGY / KNOWLEDGE / INNOVATION
Page 3 and 4: EDITORIAL BOARD Dr Anthony Davies H
Page 5 and 6: ISSUE ONE 2009 Contents Index to Ad
Page 7 and 8: © 2009 Thermo Fisher Scientific In
Page 9 and 10: SUBSCRIBE ISSUE 2009 qPCR Figure 4:
Page 11 and 12: SUBSCRIBE ISSUE 2009 qPCR chromosom
Page 13 and 14: SUBSCRIBE ISSUE 2009 qPCR assays. T
Page 15 and 16: Single Cell Gene Expression from Fl
Page 17 and 18: © 2008 Thermo Fisher Scientific In
Page 19 and 20: SUBSCRIBE ISSUE 2009 HIGH CONTENT S
Page 21 and 22: SUBSCRIBE ISSUE 2009 HIGH CONTENT S
Page 23 and 24: More Imaging Speed Introducing the
Page 25 and 26: SUBSCRIBE ISSUE 2009 LAB AUTOMATION
Page 27 and 28: ISSUE 2009 LAB AUTOMATION washed su
Page 29 and 30: SUBSCRIBE ISSUE 2009 THERMAL ANALYS
Page 31 and 32: SUBSCRIBE ISSUE 2009 THERMAL ANALYS
Page 33 and 34: SUBSCRIBE ISSUE 2009 PAT a bioproce
Page 35 and 36: SUBSCRIBE ISSUE 2009 PAT especially
Page 37: SUBSCRIBE ISSUE 2009 PAT extensive

Real time PCR - European Pharmaceutical Review

Create successful ePaper yourself

Delete template?

Save as template?